Inflammatory monocytes regulate Th1 oriented immunity to CpG adjuvanted protein vaccines through production of IL-12 by De Koker, Stefaan et al.
1SCIentIfIC RepoRts | 7:  5986 | DOI:10.1038/s41598-017-06236-6
www.nature.com/scientificreports
Inflammatory monocytes regulate 
Th1 oriented immunity to CpG 
adjuvanted protein vaccines 
through production of IL-12
S. De Koker1,3,4, L. Van Hoecke1,4, A. De Beuckelaer1, K. Roose1,4, K. Deswarte2,5, M. A. 
Willart2,5, P. Bogaert1, T. Naessens1, B. G. De Geest6, X. Saelens  1,4, B. N. Lambrecht2,5 &  
J. Grooten1
Due to their capacity to skew T cell responses towards Th1 oriented immunity, oligonucleotides 
containing unmethylated CpG motifs (CpG) have emerged as interesting adjuvants for vaccination. 
Whereas the signalling pathways in response to CpG mediated TLR9 activation have been extensively 
documented at the level of the individual cell, little is however known on the precise identity of the 
innate immune cells that govern T cell priming and polarisation to CpG adjuvanted protein antigens 
in vivo. In this study, we demonstrate that optimal induction of Th1 oriented immunity to CpG 
adjuvanted protein vaccines requires the coordinated actions of conventional DCs and of monocytes. 
Whilst conventional DCs were required for antigen presentation and initial T cell priming, monocytes 
constitute the main source of the Th1 polarising cytokine IL-12.
Agonists of Toll-like receptors (TLRs) that recognize viral and bacterial nucleic acids (TLR3, 7, 8 and 9) have the 
capacity to skew T cell responses towards Th1 oriented immunity and have emerged as promising adjuvant can-
didates1–3. TLR9 is triggered by unmethylated cytosine-phosphate-guanine (CpG) oligodeoxynucleotide motifs 
present in viral and bacterial DNA4, 5. Interaction of CpG with TLR9 induces a signalling cascade that results in 
the recruitment of MAP kinases and the activation of transcription factors (NF-κB, AP1 and IRF-7)6, 7. Whereas 
the signalling pathways in response to TLR9 activation have been extensively documented at the level of the indi-
vidual cell, little is however known on the precise identity of the innate immune cells that govern T cell priming 
and polarisation to CpG adjuvanted protein antigens in vivo.
Initial activation of effector T cell responses critically depends on three signals: antigen presentation to the T 
cell receptor (signal 1), co-stimulation (signal 2) and cytokine receptor signalling at the T cell surface (signal 3). 
Whilst signal 1 and signal 2 are sufficient to drive initial T cell proliferation, antigen-experienced T cells require 
signal 3 cytokines to acquire effector function and to differentiate into long lived memory T cells8–10. Signal 1 and 
signal 2 are typically provided by dendritic cells (DCs), the immune system’s most potent antigen presenting cells 
endowed with the unique capacity to prime naïve T cells. DCs are however highly heterogeneous and diverse 
subsets have been identified based on life cycle, ontogeny and function. Dependent on their route of entry into 
lymph nodes, DCs have been divided in lymph node resident DCs – which enter the lymph node directly from 
the bloodstream - and in migratory DCs - which reach the lymph nodes from peripheral tissues via the afferent 
lymphatics. The exact role of lymph node resident versus migratory DCs in priming T cell responses remains 
controversial and appears to be highly dependent on the nature of the antigen and of the inflammatory insult11–18. 
With regards to ontogeny, most DCs in steady state derive from a dedicated DC progenitor in the bone marrow. 
These DCs have been named conventional DCs and rely on Fms-like tyrosine kinase receptor 3 ligand (Flt3L) for 
their development19–27. Under inflammatory conditions however, also monocytes can give rise to a cell type rem-
iniscent of a DC, which hence has been named an inflammatory or monocyte derived DC. This determination 
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is largely based on their expression of CD11c and MHCII, the two cardinal markers used to identify DCs. Yet, 
to which extent monocyte derived DCs in fact also functionally resemble conventional DCs remains a matter 
of intensive debate28–35. Opposing findings regarding the capacity of monocyte derived DCs to act as antigen 
presenting cells have been reported13, 34, 36–39. Moreover, conclusions often have been confounded by the past 
lack of markers that reliably separate monocyte derived DCs from CD11b+ conventional DCs. Ambiguity also 
exists regarding the nature of the cells that deliver the necessary signal 3 to drive effector T cell differentiation40. 
In the most conservative model, signal 3 cytokines are provided by the same DC that also presents the antigen 
to the T cell. Nevertheless, signal 3 cytokines might also be supplied in trans by other DCs or even other innate 
immune cells that do not present the antigen themselves. Within this context, a growing number of studies have 
pinpointed monocytes as complex regulators of adaptive immunity. Monocytes are amongst the most abundant 
innate cells recruited to virtually any infectious insult and display a tremendous plasticity in secreting cytokines 
tailored towards the type of insult encountered32, 38, 41–48. The profound recruitment of monocytes to sites of 
inflammation thereby adds an additional, poorly understood layer to the complex cross-talk between pathogen/
adjuvant, antigen presentation and inflammation that together shape the ensuing T cell response.
Intradermal injection of CpG has been reported to mobilize vast numbers of monocytes to the lymph nodes 
of mice49 and non-human primates50. In this study, we aimed to decipher whether and how monocytes regulate T 
cell effector responses to CpG adjuvanted protein vaccines. Through a set of ex vivo and in vivo antigen presenta-
tion assays, we identified migratory DCs as the main antigen presenting cells and initiators of T cell proliferation. 
Although migratory DCs comprised both conventional DCs and monocyte derived DCs, antigen presentation 
predominantly resided within the conventional DC population. Nevertheless, through secretion of vast amounts 
of IL-12, monocytes created the appropriate inflammatory environment that supported differentiation of antigen 
experienced T cells into Th1 T cells. Taken together, our findings reveal that optimal induction of effector T cell 
responses to CpG adjuvanted vaccines requires the coordinated actions of both conventional DCs and monocytes.
Results
CpG injection dramatically expands Ly6Chi monocytes and DCs in the draining lymph 
nodes. As the major goal of this study was to address the role of Ly6Chi monocytes in the regulation of T cell 
immunity to CpG adjuvanted vaccines, we first characterized the mobilization of Ly6Chi monocytes to the blood 
and the vaccine draining lymph nodes at the indicated time intervals post CpG injection (Fig. 1A). Ly6Chi mono-
cytes were identified as live, CD45+ Ly6G− Ly6Chi CD11bhi cells. An overview of the gating strategy is shown in 
Fig. S1A. The fraction of Ly6Chi monocytes rapidly increased in the blood of CpG injected mice, peaked at around 
15% of all CD45+ Ly6G− leukocytes at 12 hours post injection and subsequently declined to baseline over time 
(Fig. 1B,C). This rapid mobilization of Ly6Chi monocytes to the blood almost coincided with their emergence in 
the draining lymph node, where Ly6Chi monocytes showed peak percentages between 12 h and 48 h post injection 
(Fig. 1D,E). Injection of the model antigen ovalbumin (OVA) without CpG did not result in significant expansion 
of Ly6Chi monocytes in blood or draining lymph nodes (Fig. S1B).
In addition to Ly6Chi monocytes, we also quantified MHCIIhi DCs and MHCIIint DCs in the draining lymph 
nodes of CpG injected mice. MHCIIhi DCs and MHCIIint DCs correspond to respectively migratory DCs and 
lymph node resident DCs and were identified based on their relative expression of CD11c and MHCII after 
exclusion of the Ly6Chi monocyte population (Fig. 1F). The absolute cell numbers of Ly6Chi monocytes, migratory 
DCs and resident DCs in the draining lymph node are shown in the graph in Fig. 1G. The relative proportions of 
Ly6Chi monocytes, migratory DCs and resident DCs over time are depicted as pie charts (Fig. 1H). The surface 
area of each pie chart is proportional to the added counts of Ly6Chi monocytes, migratory DCs and resident DCs. 
At the peak of their recruitment to the draining lymph node, Ly6Chi monocytes were 360 times more abundant 
when compared to steady state. Migratory DCs and resident DCs also showed a strong expansion, albeit less 
pronounced and with delayed kinetics when compared to Ly6Chi monocytes. Migratory DCs were about 10-fold 
increased at their peak of recruitment 48 h post injection. Resident DCs peaked at 96 h post CpG injection, when 
they showed an 8-fold increase compared to steady state lymph nodes. While Ly6Chi monocytes are 10-fold less 
abundant than migratory DCs and 20-fold less abundant than resident DCs in steady state, this picture thus 
promptly inversed after CpG injection, with Ly6Chi monocytes becoming about 8.5-fold more abundant than 
migratory DCs and 17-fold more abundant than resident DCs at the 24 h time interval.
Flt3L−/− mice and Ccr2−/− mice show impaired effector T cell responses to CpG adjuvanted vac-
cines. Conventional DC development critically relies on Flt3L25, 27, 51, 52, causing mice deficient for Flt3L to dis-
play heavily reduced numbers of conventional DCs in skin30, lung32 and lymphoid organs53. To assess the impact 
of conventional DC deficiency on the effector T cell response, we immunized Flt3L−/− mice with OVA/CpG. In 
comparison to wild type mice, Flt3L−/− mice showed a dramatic reduction in the numbers of IFN-γ secreting CD4 
and CD8 T cells as measured by ELISPOT (Fig. 2A). Flt3L−/− mice also showed less OVA-specific CD8 T cells in 
blood (Fig. 2B). Functionally, this reduced presence of OVA-specific CD8 T cells translated into a severely ham-
pered cytolytic T cell activity in immunized Flt3L−/− mice as assessed through an in vivo killing assay (Fig. 2C).
Using the same set of assays, we next addressed whether monocyte deficiency would also impact the effector 
T cell response. Although CCR2 is not required for Ly6Chi monocyte development, it is vital for the egression 
of Ly6Chi monocytes out of the bone marrow thus causing impaired recruitment of Ly6Chi monocytes to sites of 
inflammation in Ccr2−/− mice. Quantification of Ly6Chi monocytes in the draining lymph nodes confirmed that 
Ly6Chi monocytes are indeed near absent from the draining lymph nodes of CpG injected Ccr2−/− mice (Fig. S2). 
Strikingly, also Ccr2−/− mice displayed a dramatic reduction in vaccine elicited effector T cell responses with 
impaired IFN-γ secretion (Fig. 2D), lower levels of blood OVA-specific CD8 T cells (Fig. 2E) and compromised 
cytolytic activity (Fig. 2F).
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Combined, these studies thus show that generation of effector T cell responses to OVA/CpG necessitates 
monocytes in addition to conventional DCs, thereby warranting us to further assess monocyte function in dept.
Ly6Chi monocytes adopt a DC-like phenotype and infiltrate the T cell zone of the draining 
lymph node. First, we performed a flow cytometric immunophenotyping of Ly6Chi monocytes over time 
(Fig. 3A). The limited population of Ly6Chi monocytes present in steady state lymph nodes expressed low to 
Figure 1. Subcutaneous CpG injection mobilizes Ly6Chi Monocytes and DCs. (A) C57Bl/6 mice (n = 4) were 
injected in the footpad with 20 µl of CpG (100 µg/ml) and blood samples and draining popliteal lymph nodes 
were analysed at the indicated time intervals by flow cytometry. (B,D) Flow cytometry plots showing the 
frequency of Ly6Chi Monocytes in blood (B) and draining lymph node (D) of CpG injected mice at 0 h, 12 h and 
96 h post CpG injection. (C,E) Graph showing the frequency of Ly6Chi monocytes in blood (C) and draining 
lymph nodes (E) of CpG injected mice (as percentage of CD45+ Ly6G− leukocytes) over time. Mean values 
at each time interval where compared to mean values at steady state (0 h) ***P < 0.001, **p < 0.01, *p < 0.05. 
(F) Gating strategy applied to identify migratory DCs and resident DCs in popliteal lymph nodes. (G) Graph 
showing the absolute numbers of Ly6Chi monocytes, migratory DCs and resident DCs in the draining lymph 
nodes of OVA/CpG injected lice at the indicated time intervals (n = 4; mean +/− SD). (H) Pie charts depicting 
the relative proportions of Ly6Chi monocytes, migratory DCs and resident DCs in the draining lymph nodes. 
The area of the circles displayed is relative to the added counts of Ly6Chi monocytes, migratory DCs and 
resident DCs at the indicated time intervals. Data shown are representative of three independent experiments.
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intermediate levels of CD11c and MHCII and showed little expression of the co-stimulatory molecules CD86 
and CD40. When analyzed at 24 hours and 48 hours post CpG injection, the vast population of freshly recruited 
Ly6Chi monocytes displayed increased levels of CD11c, MHCII, CD40 and a pronounced upregulation of CD86, 
suggestive for involvement in T cell priming and activation. CpG recruited Ly6Chi monocytes are thus reminis-
cent of the inflammatory DCs or monocyte-derived DCs described by others28, 31, 46, 54–57. As the high affinity IgG 
receptor FcyRI (CD64) has recently emerged as a selective marker for monocyte derived DCs37, we also analyzed 
CD64 expression over time. At steady state, the few Ly6Chi monocytes present displayed low levels of CD64. 
Nonetheless, CpG recruited Ly6Chi monocytes showed a strong upregulation of CD64 upon differentiation into 
monocyte derived DCs.
Based on the data above, CpG evoked Ly6Chi monocytes appear to acquire the necessary machinery to 
efficiently interact with T cells. To assess whether Ly6Chi monocytes physically interact with T cells, we cryo-
sectioned the draining lymph nodes of mice 48 h after CpG injection, when Ly6Chi monocytes peak and display 
a CD64hi CD11cint phenotype. Sections were stained for CD3 to identify T cells and for CD11c to identify 
DCs. Because Ly6C is widely expressed by non-monocyte populations, we used CD64 as marker to stain for 
monocytes and monocyte derived DCs. Besides monocytes, CD64 expression is restricted to macrophages24, 
58. In steady state lymph nodes, CD11c+ DCs were visible within the T cell zone whereas CD64+ cells were 
excluded from the T cell zone and predominantly localized to the subcapsular and medullary sinuses. In 
addition, these CD64+ cells did not co-stain for CD11c and thereby must correspond to macrophages. CpG 
injection altered the intranodal distribution of CD64+ cells. Besides being localized in the lymph nodes’ 
sinuses, large clusters of CD64+ cells now became visible within the T cell zone. These T cell zone infiltrating 
CD64+ cells also co-stained for CD11c (Fig. 3B, white arrows) and thereby perfectly matched the characteristic 
CD64+ CD11cint-hi expression pattern we observed on monocyte derived DCs by flow cytometry.
Ly6Chi monocytes are the dominant antigen containing population in the draining lymph node. 
Using AlexaFluor647-labeled ovalbumin (OVA-AF647), we monitored antigen uptake by Ly6Chi monocytes, 
migratory DCs and resident DCs in the draining lymph node. To reliably identify cells as being OVA-AF647+, 
the same dose of unlabeled OVA mixed with CpG was injected as negative control. An overview of the gating 
strategy applied is shown in Fig. 4A. In the draining lymph node, migratory DCs showed the largest fraction of 
OVA-AF647+ cells from 12 h to 48 h post injection (Fig. 4B). Nevertheless, also a significant fraction of Ly6Chi 
monocytes contained antigen at these time intervals. Resident DCs consistently were the least antigen positive. 
When looking at the absolute number of antigen positive cells however, Ly6Chi monocytes/monocyte derived 
DCs were clearly the dominant antigen containing population at 24 h and 48 h post injection (Fig. 4C). At 24 h 
post CpG injection, when the draining lymph node showed the highest number of OVA-AF647+ cells, OVA 
containing Ly6Chi monocytes were 3.3 times more abundant compared to OVA containing migratory DCs and 
almost 20 times more abundant compared to OVA containing resident DCs (n = 5; mean =/− SD). Data shown 
are representative of three independent experiments.
Figure 2. Flt3L−/− mice and Ccr2−/− mice show impaired effector T cell responses. Analysis of the effector 
T cell response to OVA/CpG vaccination. (A–C) Comparison of effector T cell responses between WT and 
Flt3L−/− mice. (D–F) Comparison of effector T cell responses between WT and Ccr2−/− mice. (A,D) ELISPOT 
analysis determining the numbers of IFN-γ secreting T cells (n = 6; mean +/− SD). (B,E) Flow cytometric 
quantification of OVA-specific CD8 T cells in blood (n = 5/group; mean +/− SD). (C,F) OVA-specific 
cytotoxicity as measured by an in vivo killing assay (n = 7/group; mean +/− SD). ****P < 0.0001, ***p < 0.001. 
Data shown are representative of three independent experiments.
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Migratory DCs are the major antigen presenting cells in case of CpG adjuvanted protein vaccination. 
Because Ly6Chi monocytes acquired antigen, infiltrated the T cell zone of the lymph node and adopted a MHCIIint 
CD11cint DC-like phenotype, we assessed their ability to act as antigen presenting cells. Ly6Chi monocytes as 
well as migratory DCs and resident DCs were sorted them from the draining lymph nodes of mice immunized 
Figure 3. Phenotypic characterization and intranodal distribution of Ly6Chi monocytes. (A) Phenotypic 
characterization of Ly6Chi monocytes in the draining lymph node in response to subcutaneous CpG injection. 
The levels of CD11c, MHCII, CD86, CD40 and CD64 of ly6Chi monocytes are shown at 0 h, 24 h and 48 h 
after subcutaneous CpG injection. (B) Confocal images of popliteal lymph nodes in steady state and following 
footpad injection of CpG. Sections were stained for CD3 (blue), CD11c (red) and CD64 (green) to visualize T 
cells, DCs and Ly6Chi monocytes.
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24 hours earlier with OVA/CpG and co-cultured with CFSE labelled OT-I or OT-II cells without further ex vivo 
addition of antigen. As shown in Fig. 5A, Ly6Chi monocytes and resident DCs totally failed to elicit T cell prolif-
eration. In contrast, the migratory DC subset provoked strong OT-I and OT-II proliferation, thereby identifying 
this DC subset as the prime antigen presenting cell type. Migratory DCs derive from interstitial DCs that have 
migrated from the skin and carry antigen to the lymph node in a CCR7 dependent fashion59. Ccr7−/− mice indeed 
showed an almost total lack of migratory DCs (MHCIIhi DCs) in the draining lymph nodes at 48 h after CpG/
OVA injection (Fig. 5B,C) – the time point we showed migratory DCs to peak in wild type mice. Conversely, 
Ccr7−/− mice showed unaltered Ly6Chi monocyte recruitment, which indicates Ly6Chi monocytes do not require 
CCR7 for lymph node influx and thus infiltrate the draining lymph node directly from the blood. This combi-
nation of dramatically reduced migratory DC influx and unaltered Ly6Chi monocyte recruitment made Ccr7−/− 
mice ideally suited to address the role of migratory DCs in antigen presentation in vivo. As can be appreciated 
from Fig. 5D,E, proliferation of OVA-specific OT-I T cells was dramatically compromised in OVA/CpG immu-
nized Ccr7−/− mice. These data thus confirm the findings obtained from the ex vivo proliferation assay and firmly 
establish migratory DCs as the major antigen presenting population to CpG adjuvanted protein vaccination.
Antigen presentation mainly resides within migratory DCs of conventional ontogeny. Recent 
studies have indicated that Ly6Chi monocytes can strongly downregulate Ly6C expression upon differentiation 
into monocyte derived DCs in inflamed peripheral tissues30, 32, 54. When such monocyte derived DCs subse-
quently migrate to the draining lymph node, they become Ly6Clo-int CD11b+ CD11c+ MHCIIhi, which makes 
them extremely difficult to distinguish from conventional CD11b+ migratory DCs - which are Ly6C− CD11b+ 
CD11c+ MHCIIhi - based on Ly6C expression only. Recently, the combined expression of Ly6C and of CD64 has 
been documented to enable a more reliable separation of monocyte derived DCs and conventional DCs in murine 
models of house dust mite allergy and of Alum based immunization32, 37.
To delineate whether cells of monocyte origin contribute to the antigen presenting migratory DC population, 
we monitored the expression of Ly6C and CD64 on the CD24− CD11b+ MHCIIhi migratory DC population 
before and after OVA/CpG injection. Figure 6A depicts the gating strategy applied, whereas Fig. 6B depicts the 
expression of Ly6C versus CD64 on CD24− CD11b+ migratory DCs at the indicated time intervals after CpG 
injection. In steady state lymph nodes, virtually all CD11b+ migratory DCs lacked Ly6C and CD64, in accord-
ance with their described conventional DC nature. Upon CpG injection, a marked increase in the proportion 
and absolute numbers of CD11b+ migratory DCs that displayed a Ly6Clo-int CD64lo-int phenotype was observed 
(Fig. 6B–D). To unambiguously mark these Ly6Clo-int CD64lo-int CD11b+ MHCIIhi DCs as migratory DCs of 
monocyte origin, we quantified their numbers in the draining lymph nodes of respectively CpG injected wild 
type mice, Ccr2−/− mice and Ccr7−/− mice (Fig. 6E,F). In line with a monocyte origin, the Ly6Clo-int CD64lo-int 
CD11b+ migratory DC population was near absent in Ccr2−/− mice. Conversely, the Ly6C− CD64− migra-
tory DC population was unaffected by CCR2 deficiency, confirming these cells correspond to bona fide conven-
tional DCs. Both CD11b+ migratory DC subtypes were strongly affected by CCR7 deficiency, which shows that 
migratory DCs depend on CCR7 to reach the lymph nodes regardless of a monocyte or conventional DC origin. 
Very little is known regarding the capacity of monocyte derived DCs to present antigen in vivo. To address the 
relative contributions of monocyte derived migratory DCs and conventional migratory DCs to antigen presenta-
tion, we compared the proliferation of adoptively transferred OT-I and OT-II T cells between wild type mice, 
Figure 4. Antigen uptake by monocytes, migratory DCs and resident DCs in lymph nodes, (A) Gating strategy 
applied to identify OVA-AF647+ Ly6Chi monocytes, migratory DCs and resident DCs in the draining lymph 
nodes of OVA-AF647/CpG injected mice. (B,C) Graphs showing respectively the percentages (B) and absolute 
numbers (C) of Ly6Chi monocytes, migratory DCs and resident DCs that have acquired OVA-AF647 in the 
draining lymph nodes at the indicated time intervals post OVA-AF647 injection (n = 4). Data are representative 
of three independent experiments.
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Flt3L−/− mice and Ccr2−/− mice immunized with OVA/CpG. Within the migratory DC population, Ccr2−/− mice 
lack monocyte derived DCs while Flt3L−/− mice have a deficit in conventional DCs. Little or no differences in 
the percentages of OT-II (Fig. 6G,H) or OT-I (Fig. 6I,J) T cells having undergone extensive T cell proliferation 
were observed between WT and Ccr2−/− mice, arguing against a major role of monocytes and their monocyte 
derived migratory DC descendants in antigen presentation. Conversely, the deficit in conventional DCs present 
in Flt3L−/− mice did cause a strongly diminished T cell proliferation in these mice. Although these data do not 
formally exclude that migratory monocyte DCs can present antigen, they do identify conventional migratory DCs 
as the most important antigen presenting DC population.
Ly6Chi monocytes constitute the major source of IL-12 that drives Th1 oriented T cell immu-
nity. Despite monocytes having no major contribution in antigen presentation to naïve T cells, effector T cell 
responses are dramatically impaired in OVA/CpG immunized Ccr2−/− mice. Consequently, we explored whether 
Ly6Chi monocytes would be an important source of IL-12, the most prominent signal 3 cytokine driving Th1 
oriented immunity. To this end, we sorted Ly6Chi monocytes, migratory DCs and resident DCs from the pooled 
draining popliteal lymph nodes of mice injected 24 h earlier with OVA/CpG in the footpad. Sorted cells were 
subsequently cultured either without further stimulation or stimulated with a low dose of LPS and anti-CD40 as 
previously described by Nakano et al.47 Strikingly, Ly6Chi monocytes comprised the sole population that secreted 
detectable amounts of IL-12 - even in the absence of further LPS/CD40 stimulation (Fig. 7A). Ly6Chi monocytes 
also produced high levels of the inflammatory cytokines IL-1β, TNF-α and IL-6, whereas these cytokines were 
not detected in the supernatant of cultured migratory DCs and resident DCs. To avoid confounding results due to 
potential differences in viability between ex vivo cultured monocytes and DCs, we determined the relative tran-
script levels of IL-12 p35 in freshly sorted Ly6Chi monocytes, migratory DCs and resident DCs. In line with the 
results from the ex vivo culture, sorted Ly6Chi monocytes showed far higher transcript levels of IL-12 compared to 
migratory and resident DC populations (Fig. 7B). This prominent role of Ly6Chi monocytes in IL-12 production 
Figure 5. Migratory DCs constitute the major antigen presenting population to CpG adjuvanted protein 
vaccination. (A) Proliferation of CFSE labelled OT-I and OT-II cells following incubation with respectively 
Ly6Chi monocytes, migratory DCs and resident DCs sorted from the pooled draining lymph nodes of 30 
mice injected with OVA/CpG. (n = 5; mean +/− SD). Data shown are representative of two independent 
sorting experiments. (B–C) Flow cytometric comparison of Ly6Chi monocyte and migratory DC influx in the 
draining lymph nodes of CpG injected WT and Ccr7−/− mice. (B) Contour plots showing Ly6Chi monocyte 
and migratory DC frequencies.(C) Graph showing the absolute numbers of Ly6Chi monocytes and migratory 
DCs (n = 5; mean +/− SD). (D–E) Flow cytometric analysis of OT-I proliferation in the draining lymph 
nodes of WT and Ccr7−/− mice immunized four days earlier with OVA/CpG. (D) Histogram overlay of OT-I 
proliferation in WT and Ccr7−/− mice. (E) Graph quantifying the total numbers of OT-I cells and the number 
of OT-I cells having undergone over 4 divisions (n = 5; mean +/− SD). Data are representative of three 
independent experiments.
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Figure 6. Migratory DCs are of composed of monocyte derived DCs and conventional DCs. (A) Gating 
strategy applied to identify Ly6Clo-int CD64lo-int DCs within the CD11b+ CD24− migratory DC gate. (B) Flow 
cytometry plots of Ly6C and CD64 expression within the CD11b+ CD24− migratory DC at the indicated 
time intervals post CpG injection. (C,D) Frequencies and absolute numbers of Ly6Clo-int CD64lo-init CD11b+ 
CD24− migratory DCs and Ly6C− CD64− CD11b+ CD24− migratory DCs. (E,F) Dot plots (E) and absolute 
cell counts (F) of Ly6Clo-int CD64lo-int CD11b+ CD24− migratory DCs and Ly6C− CD64− CD11b+ CD24− 
migratory DCs in the draining lymph node of wild type (WT), Ccr2−/− mice and Ccr7−/− mice at 48 h post CpG 
injection. Data are shown as means +/− SD (n = 5). (G,I) Histogram plots showing the proliferation of OT-II 
(G) and of OT-I. (I) T cells in the draining lymph nodes of OVA/CpG immunized wild type (WT), Ccr2−/− 
mice and Flt3L−/− mice. (H,J) Graphs displaying the percentages of OT-II (H) and OT-I (J) T cells having 
undergone over 4 divisions in the draining lymph nodes of wild type (WT), Ccr2−/− mice and Flt3L−/− mice 
(n = 6; means +/− SD). Data are representative of two independent experiments.
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was further confirmed by quantification of IL-12 titers in the supernatans of lymph nodes obtained from wild type 
and Ccr2−/− mice injected with CpG. Consistent with the sorting results, the lack of Ly6Chi monocytes in Ccr2−/− 
mice virtually abrogated IL-12 production in the draining lymph nodes of CpG injected Ccr2−/− mice (Fig. 7C).
Figure 7. Ly6Chi monocytes constitute the major source of IL-12 that drives IFN-γ T cell responses. (A) Graphs 
showing cytokine production by Ly6Chi monocytes, migratory DCs and resident DCs sorted from the pooled 
popliteal lymph nodes of mice (n = 40) injected with CpG 24 h earlier. 2 × 105 sorted cells were cultured for 48 h 
either without further stimulation or stimulated with a low dosis of LPS (100 ng/ml) and anti-CD40 (1 µg/ml). 
All data points indicate means +/− SD for five replicates. (B) Relative IL-12 mRNA transcript levels in Ly6Chi 
monocytes, migratory DCs and resident DCs sorted from the pooled popliteal lymph nodes of mice (n = 20) 
injected with CpG 24 h earlier. (C) IL-12p70 titers determined in the supernatans of the draining lymph nodes 
isolated from CpG injected WT and Ccr2−/− mice. Lymph nodes were isolated 24 h post CpG injection and 
cultured for an additional 48 h ex vivo (n = 5; mean +/− SD). (D) Schematic overview of the procedure applied 
to generate mixed IL-12−/−/Ccr2−/− chimeric mice. (E) IL-12 p70 titers in the supernatans of the draining and 
non-draining lymph nodes of CpG injected WT/IL-12−/− and Ccr2−/− /IL-12−/− chimeric mice (n = 5; mean 
+/− SD). (F) ELISPOT quantification of the numbers of IFN-γ secreting T cells of WT/IL-12−/− and Ccr2−/− /
IL-12−/− chimeric mice immunized with OVA/CpG through a prime booster schedules (n = 5; mean +/− SD). 
Data shown are a representative of two independent experiments.
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To determine whether monocyte-derived IL-12 is vital for the induction of IFN-γ producing effector T cells, 
we exploited the selective dependency of Ly6Chi monocytes but not conventional DCs on CCR2 to reach the 
draining lymph nodes by generating Ccr2−/−/IL-12−/− mixed chimeric mice (Fig. 7D). Lethally irradiated wild 
type mice were reconstituted with respectively a 1:1 bone marrow mixture of wild type mice and IL-12−/− mice or 
a 1:1 bone marrow mixture of Ccr2−/− mice and IL-12−/− mice. In wild type/IL-12−/− chimeric mice, half of the 
Ly6Chi monocytes and half of the conventional DCs derive from the wild type background and are thereby genet-
ically competent to produce IL-12. In Ccr2−/− /IL-12−/− chimeric mice, half of the conventional DCs (derived 
from the Ccr2−/− background) are still genetically competent to produce IL-12 but only monocytes derived from 
the IL-12−/− background can reach the lymph nodes. Quantification of IL-12 titers in the culture supernatans 
of the draining lymph nodes of wild type/IL-12−/− mice and of Ccr2−/−/IL-12−/− chimeric mice injected with 
CpG validated that IL-12 production is indeed heavily compromised when monocytes cannot produce IL-12 
(Fig. 7E). To address the functional impact of this monocyte derived IL-12 on the effector T cell response, we next 
immunized wild type/IL-12−/− mice and Ccr2−/−/IL-12−/− mice with OVA/CpG and determined the numbers of 
IFN-γ secreting T cells by ELISPOT. In comparison to wild type/IL-12−/− chimeric mice, Ccr2−/−/IL-12−/− chi-
meric mice showed a 3.7-fold reduction in the number of IFN-γ secreting CD4 T cells and a 5-fold reduction in 
the number of IFN-γ secreting CD8 T cells. Taken together, these data identify monocytes as the major source 
of IL-12 and stress the importance of monocyte derived IL-12 for optimal induction of IFN-γ secreting CD8 and 
CD4 T cells (Fig. 7E).
Discussion
Due to their capacity to instigate Th1 oriented immunity against co-delivered antigens, CpG oligo’s have emerged 
as promising vaccine adjuvants. In this study, we have elucidated the main innate immune cells that regulate the 
effector T cell response to CpG adjuvanted protein vaccines. Our data highlight that the immune-potentiating 
actions of CpG require the coordinated actions of conventional DCs and monocytes. Antigen presentation in 
the draining lymph node is predominantly exerted by conventional DCs that have migrated from the inflamed 
injection site to the draining lymph node. Monocytes contribute little to antigen presentation in this setting, but 
instead constitute the major source of the signal 3 cytokine IL-12 required to differentiate antigen experienced T 
cells into Th1 and cytolytic T cells. These data thereby nicely complement a recent study in which monocytes were 
also shown to support B cell immunity to CpG adjuvanted protein vaccination through inflammatory secretion49. 
More generally, our findings enforce the emerging viewpoint that monocytes orchestrate the characteristics of 
the T cell response by shaping the local inflammatory environment antigen experienced T cells are exposed to.
Over the past years, monocytes have been implicated in the regulation of T cell immunity either through 
antigen presentation34, 46, 60 or through secretion of cytokines that stimulate effector T cell differentiation44, 48. 
Conversely, an equal number of studies found no involvement of monocytes in antigen presentation61, 62 and a 
recent study by the Steinman lab argued against any involvement of monocytes in shaping T cell immunity upon 
vaccination with protein antigens adjuvanted with the TLR3 agonist pIC or with the TLR4 agonist MPL13. With 
the role of monocytes emerging as extremely complex and context dependent, we set out to determine whether 
the vast population of monocytes recruited by CpG is implicated in the strong Th1 polarizing properties of this 
promising adjuvant. Immunization studies in mice respectively lacking conventional DCs (Flt3L−/−) or mono-
cytes (Ccr2−/−) in the vaccine draining lymph node indicated that both monocytes and conventional DCs are 
required for the Th1 polarized effector T cell response upon CpG based immunization. As Ly6Chi monocytes 
acquired typical phenotypic features required for antigen presentation – including an upregulated expression 
of MHCII and of co-stimulatory molecules upon lymph node entry - we hypothesized these monocytes might 
act as antigen presenting cells. T cell proliferation assays in Ccr2−/− mice and co-cultures between T cells and 
Ly6Chi monocytes sorted from the draining lymph nodes of CpG injected mice however unmasked the incapacity 
of Ly6Chi monocytes to present antigen. Instead, sorted migratory DCs were identified to possess potent anti-
gen presenting capacities. The dramatic impairment in T cell proliferation in the lymph nodes of Ccr7−/− mice 
further strengthened these observations and firmly established migratory DCs as the main antigen presenting 
cells to OVA/CpG. The crucial role of migratory DCs in antigen presentation is in line with early reports on the 
antigen presenting capacities of skin derived migratory DCs18, 59 and with two recent publications that identified 
migratory DCs as antigen presenting cells to vaccination with Alum and AS01 as adjuvants37, 63. Most monocytes 
entered the vaccine draining lymph node directly from the blood, displayed a Ly6Chi CD64hi MHCIIint phenotype 
and failed to present antigen. Nevertheless, within the migratory DC population, we also identified a second, far 
scarcer population of DCs that are of monocytic origin. These monocyte derived migratory DCs expressed lower 
levels of Ly6C and CD64 compared to their Ly6Chi monocyte counterparts but were still distinguishable from 
conventional CD11b+ migratory DCs23, 30, 37. Similar populations of monocyte derived migratory DCs have been 
documented in response to Leishmania infection54, to house dust mite32, 38 and to immunization with Alum or 
with AS01 as adjuvants63. In case of Alum adjuvanted vaccination, sorted monocyte derived migratory DCs were 
capable of presenting antigen to CD4 and CD8 T cells upon ex vivo addition of antigen. Similarly, Plantinga et 
al. demonstrated the capacity of monocyte derived migratory DCs to present antigen to CD4 T cells after house 
dust mite challenge32. Nevertheless, the same study also revealed that monocyte derived DCs are far less efficient 
in traveling to lymph nodes when compared to their conventional DC counterparts, a feature that restricted their 
contribution to T cell priming to high doses of house dust mite. Although we were unable to sort sufficient num-
bers of monocyte derived migratory DCs with adequate purity to directly address their capability to present anti-
gen ex vivo, monocyte deficiency has little impact on early T cell proliferation assessed in Ccr2−/− mice, whereas 
the conventional DC deficit in Flt3L−/− mice results in a marked T cell proliferation reduction. Taken together, 
these studies thereby demonstrate the necessity of conventional migratory DCs for antigen presentation in vivo 
whilst monocyte derived migratory DCs appear to be largely redundant.
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Despite initial proliferation of OVA-specific T cells in Ccr2−/− mice, differentiation of primed T cells into 
IFN-γ secreting T cells and cytolytic T cells is severely hampered in OVA/CpG immunized Ccr2−/− mice. Two 
major lines of evidence indicate that these defective effector T cell responses in Ccr2−/− mice are in fact caused 
by a lack of monocytes that secrete the required IL-12 to drive T cell differentiation. First, when sorted from the 
draining lymph nodes of CpG injected mice, Ly6Chi monocytes were the most prominent producers of IL-12. 
Draining lymph node cultures of Ccr2−/− mice and of IL-12−/−/Ccr2−/− chimeric mice showed dramatically 
reduced IL-12 titers. Second, OVA/CpG immunized IL-12−/−/Ccr2−/− chimeric mice – where monocytes are 
present in the lymph node but fail to produce IL-12 - displayed reduced numbers of IFN-γ secreting T cells.
Akin our findings, Nakano et al. identified monocyte derived DCs as the sole producers of IL-12 and major 
instigators of Th1 immunity to immunization with Complete Freund’s Adjuvant (CFA) – which amongst other 
PRRs triggers TLR947. Monocytes and monocyte derived DCs have also been strongly implicated in the reg-
ulation of Th1 immunity to parasite infections that trigger TLR9. Léon et al. demonstrated that monocytes 
differentiate into monocyte derived DCs upon Leishmania infection and drive anti-Leishmanial Th1 immune 
responses through IL-12 production54. More recently, monocytes were also shown to provide a robust IL-12 burst 
in response to Toxoplasma gondii infection64. Nonetheless, the role of monocytes in these parasitic infections as 
regulators of Th1 immunity is still contested as other studies identified Batf3 dependent conventional DCs as vital 
sources of IL-12 to Leishmania65 and to Toxoplasma infection66. A recent study by Shah et al. appears to reconcile 
these apparently opposing findings. In this report, differentiation of CD8 cells into IFN-γ secreting effector T cells 
upon Toxoplasma infection was shown to require the coordinated actions of conventional DCs and monocyte 
derived DCs, with the former providing a limited early source of IL-12 and the latter supplying a more robust 
second IL-12 burst that drives effector differentiation of the expanding antigen-experienced cells64. In our study, 
we failed to detect IL-12 in lymph node cultures of sorted migratory and resident Ly6C− DCs – which include 
the Batf3 dependent DC subset. As Batf3 dependent DCs represent a minor fraction of these sorted migratory 
and resident Ly6C− DC cultures, our experimental approach might have missed IL-12 production by these DCs. 
Nonetheless, IL-12 titers of lymph node cultures derived from CpG injected Ccr2−/− and of Ccr2−/−/IL-12−/− 
mice were reduced to baseline, thus firmly establishing monocyte derived DCs as the main source of IL-12. 
In summary, our findings add to the body of literature now challenging the conservative model of one antigen 
presenting DCs delivering all three signals that govern T cell immunity. Instead, antigen presenting DCs appear 
to be assisted by monocytes and potentially other innate immune cells that integrate pathogen derived and envi-
ronmental cues into the secretion of cytokines that tune the T cell response mainly initiated by conventional DCs. 
Designing vaccine approaches that harness this astonishing plasticity of monocytes to shape T cell immunity thus 
represents an interesting avenue to enhance the efficacy of vaccines.
Methods
Vaccine formulations and immunizations. OVA was purchased from Worthington. OVA-Al-647 and 
OVA-Al 488 was purchased from Molecular probes. OVA(257–264) and OVA(323–339) peptide epitopes were 
purchased from Anaspec Inc. ODN1826 (CpG; TCC ATG ACG TTC CTG ACG TT) is a 20-mer with a nucle-
ase-resistant phosphorothioate backbone and was purchased from Invivogen. ODN1826 is a class B CpG that has 
potent Th1 skewing properties in mice. Mice were immunized either subcutaneous in the footpad (20 µl volume) 
or at the tail basis (100 µl volume) with a mixture of OVA (100 µg/ml) and CpG (100 µg/ml).
Mice. C57BL/6 J mice were purchased from Janvier. OT-I transgenic mice, OT-II transgenic mice and CCR2−/−, 
CCR7−/− and Flt3L−/− mice were bred in house. IL-12 p40−/− mice were a kind gift by dr. E. Muraille (Université 
Libre de Bruxelles)67. All animal experiments were approved by the animal ethical committee of Ghent University. 
All experiments and procedures were performed in accordance with the relevant guidelines and legislations.
Kinetics of Ly6Chi Mo and DC recruitment to blood and popliteal lymph nodes. To analyze mono-
cyte and DC recruitment in response to CpG, 20 µl of a 100 µg/ml ODN1864 solution was injected into the foot-
pad of C57BL/6 J mice. At the indicated time intervals post injection, blood samples were collected through 
the tail vein followed by ACK (Thermo Fisher Scientific) mediated red blood cell lysis. Alternatively, mice were 
euthanized and the DLNs were dissected. Single cell suspensions of DLN were prepared through incubation with 
collagenase type IV (Sigma-Aldrich) and passed through a 70 µm cell strainer (BD Falcon).
After treatment with 2.4G2 Ab for 5 min to block the FcR, PBMCs or lymph node cell suspensions were 
stained with the following anti-mouse Abs: anti-CD45-V450, anti- MHCII-FITC, anti-CD86-PE, anti-CD40- 
PE, anti-CD64-APC, anti-F4/80-APC, anti-Ly6C-PE-Cy7, anti-CD11b-APC-Cy7 (all BD Biosciences), 
Ly6G-PerCP-Cy5.5, CCR2-APC (eBioscience), CD64-BV421 (BioLegend) and CD11c-PE-TxR (R & D systems). 
Death cells were identified by staining with aqua life/dead stain (Invitrogen). Fluorescent events were acquired 
using an LSRII flow cytometer (BD Biosciences) and analyzed using FlowJo software. After exclusion of dead 
cells, granulocytes were identified as CD45+ CD11b+ Ly6C+ Ly6G+ cells and Monocytes as CD45+ Ly6Chi 
CD11bhi Ly6G- cells. Following exclusion of granulocytes and Monocytes in the LN, DCs were subdivided into 
MHCIIhi DCs and MHCIIint DCs.
OT-I and OT-II proliferation assays. The ex vivo Ag presentation assays were performed using a protocol 
adapted from Langlet et al. OVA-specific CD8+ T and CD4+ T cells were isolated from OTI and OTII trans-
genic mice, respectively, and labeled with 10 µM CFSE. 105 OT-I T cells or 105 OT-II T cells were subsequently 
co-cultured for 48 hours with respectively 104 sorted Ly6Chi monocytes, MHCIIhi DCs or MHCIIint DCs obtained 
from the DLN of mice previously (24 h) immunized with 20 µl of an OVA (100 µg/ml)/CpG (100 µg/ml) mixture. 
OT-I and OT-II proliferation was determined by the loss of CFSE fluorescence by flow cytometry. Sorts were 
performed using a FACSAria sorter (BD Biosciences).
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In vivo antigen presentation assays were performed through adoptive transfer of 2 × 105 CFSE labeled OT-I or 
OT-II cells to respectively WT C57BL/6 J mice, CCR2−/− mice, CCR7−/− mice and Flt3L−/− mice 48 hours prior 
to OVA/CpG immunization. Four days post immunization, DLN were dissected, stained with anti-CD3-V450, 
anti-CD4-PerCP, anti-CD8-PerCP, anti-Vα2 TCR-PE, anti-CD19-APC-Cy7 (all BD Biosciences), PE-labeled 
SIINFEKL specific dextramers (Immudex) and measured on a LSRII flow cytometer (BD Biosciences).
Characterization of antigen uptake. To evaluate antigen uptake by Ly6Chi monocytes, MHCIIhi and 
MHCIIint DCs in the lymph node, Alexa647-labbeled OVA (100 µg/ml) was injected into the footpad of mice 
mixed with ODN1864 (100 µg/ml). Popliteal lymph nodes were dissected at the indicated time intervals and single 
cell suspensions were stained with aqua life/dead, Fc block, CD45-MHCII-FITC, Ly6-PE-Cy7, CD11b-APC-Cy7 
(BD-biosciences), CD11c-PE-TxR (R & D systems) and Ly6G-PerCP-Cy5.5 (eBioscience). To determine the 
OVA-Alexa647 positive monocyte/DC gate, mice were injected with a mixture of unlabeled OVA (100 µg/ml) 
and ODN1864 (100 µg/ml).
Generation of chimeric mice. WT C57BL/6 J mice were irradiated with an 8 Gy dose and reconstituted 
either with a 1:1 mixture of bone marrow from IL-12−/− mice and WT mice or a with 1:1 mixture of bone marrow 
from IL-12−/− mice and from CCR2−/− mice.
Quantification of cytokines analysis. To quantify cytokine production in response to CpG injection, 
DLN were dissected 24 hours post CpG injection and cultured for an additional 24 h ex vivo in complete RPMI 
(Gibco). Cytokine levels of IL-12p70, were determined by Luminex (BioRad) according to the manufacturer’s 
protocol.
To address cytokine production by sorted Ly6Chi Monocytes, MHCIIhi DCs and MHCIIint DCs, these cells 
were sorted from the pooled DLN of 40 mice injected 24 hours earlier with 20 µl of CpG (100 µg/ml). 2 × 105 
cells were cultured in a volume of 200 µl either without further stimulation or in the presence of 10 ng/ml LPS 
(Invivogen) and 1 µg/ml anti-CD40 (BD Biosciences). Cytokine levels, were determined by Luminex (BioRad) 
according to the manufacturer’s protocol.
Total RNA preparation and real-time quantitative PCR. The isolation of the RNA was performed 
with the RNeasy Plus Micro Kit (Qiagen, Hilden, Germany). cDNA was synthesized with an Transcriptor 
First Strand cDNA synthesis kit (Roche Molecular Systems, Basel, Switzerland). The real-time quantitative 
PCR was performed on a LightCycler 480 (Roche Molecular Systems, Basel, Switzerland) by using the sensi-
FAST SYBR No-ROX kit (Bioline, London, United Kingdom). Primers for interleukine 12 p35 (IL12p35) 
(sense, 5′-AGCCTCCTCCTTGTGGCTA-3′ and antisense, 5′-TGTGCTGGTTTTATCTTTTGTG-3′) 
and 60 S ribosomal protein L13 a (Rpl13a; reference housekeeping gene for normalization) (sense 
5′-CCTGCTGCTCTCAAGGTT-3′ and antisense, 5′-TGGTTGTCACTGCCTGGTACTT-3′) were used.
Elispot analysis. IFN-γ Elispots were purchase at eBioscience and used according to the manufacturer’s 
instructions. In brief, 2 × 105 splenocytes of immunized mice were restimulated with respectively 10 µg/ml OVA 
(257–264) or OVA(323–339) for 24 h on pre-coated Elispot plates.
In vivo killing assay. To quantify the strength of the vaccine evoked cytotoxic T cell response, an in vivo 
killing assay was performed as described earlier68. In brief, vaccinated mice were challenged with a 1:1 mixture 
of peptide pulsed CFSElo naïve splenocytes (target cells) and CFSEhi unpulsed naïve splenocytes. Four days later, 
spleen were dissected and the ratio of target versus non-target cells was determined by flow cytometry.
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